Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Targets $20M Series D Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biodesix has closed on the first of two tranches of a financing round targeting $20 million, a company spokesman confirmed today.

The Broomfield, Colo.-based companion diagnostics firm declined to provide details about the tranches, but in a document filed with the US Securities and Exchange Commission, Biodesix said that to date, it has raised $10 million in the round. The offering is in the form of equity.

In an e-mail to GenomeWeb Daily News, the spokesman said the round is a Series D financing, and proceeds will be used to support commercialization of its VeriStrat proteomic test to guide physicians treating patients with non-small cell lung cancer.

The funds will also support collaborations with biotechnology and pharmaceutical companies, he added. In January, a company official told GWDN that Biodesix would pursue collaborations with pharma firms to increase adoption of the test.

Participants in the round include existing investors.

The current funding follows a Series C financing round that the company completed in November that raised $7.1 million to further develop the VeriStrat test.

Biodesix plans to pursue clearance from the US Food and Drug Administration for the test, which is performed in Biodesix's CLIA laboratory. In March VeriStrat received certification from the New York State Department of Health, making it available in all 50 states.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.